Fetal bovine serum and immunogenicity of rat colon cancer cells

There is growing evidence that DNA repair factors have clinical value for cancer treatment. Nucleotide excision repair (NER) proteins, including excision repair cross-complementation group 2 (ERCC2), play a critical role in maintaining genome integrity. Here, we examined ERCC2 expression following epigenetic combination drug treatment. Attention was drawn to ERCC2 for three reasons. First, from online databases, colorectal cancer (CRC) patients exhibited significantly reduced survival when ERCC2 was overexpressed in colon tumors. Second, ERCC2 was the most highly downregulated RNA transcript in human colon cancer cells and rat tumors after treatment with the histone deacetylase 3 (HDAC3) inhibitor sulforaphane (SFN) plus JQ1, which is an inhibitor of the bromodomain and extraterminal domain (BET) family. Third, as reported here, RNA-sequencing of polyposis in rat colon (Pirc) polyps following treatment of rats with JQ1 plus 6-methylsulfinylhexyl isothiocyanate (6-SFN) identified Ercc2 as the most highly downregulated gene. The current work also defined promising second-generation epigenetic drug combinations with enhanced synergy and efficacy, especially in metastasis-lineage colon cancer cells cultured as 3D spheroids and xenografts. This investigation adds to the growing interest in combination approaches that target epigenetic ‘readers’, ‘writers’, and ‘erasers’ that are deregulated in cancer and other pathologies, providing new avenues for precision oncology and cancer interception.

Download Full-text

PEGylated Nanographene Oxide in Combination with Near-Infrared Laser Irradiation as a Smart Nanocarrier in Colon Cancer Targeted Therapy

Pharmaceutics ◽

10.3390/pharmaceutics13030424 ◽

2021 ◽

Vol 13 (3) ◽

pp. 424

Author(s):

Milena Georgieva ◽

Zlatina Gospodinova ◽

Milena Keremidarska-Markova ◽

Trayana Kamenska ◽

Galina Gencheva ◽

...

Keyword(s):

Colon Cancer ◽

Targeted Therapy ◽

Zeta Potential ◽

Cancer Cells ◽

Near Infrared ◽

Cancer Therapies ◽

Colon Cancer Cells ◽

Biological Compatibility ◽

Fetal Bovine ◽

Cancer Targeted Therapy

Anti-cancer therapies that integrate smart nanomaterials are the focus of cancer research in recent years. Here, we present our results with PEGylated nanographene oxide particles (nGO-PEG) and have studied their combined effect with near-infrared (NIR) irradiation on low and high invasive colorectal carcinoma cells. The aim is to develop nGO-PEG as a smart nanocarrier for colon cancer-targeted therapy. For this purpose, nGO-PEG nanoparticles’ size, zeta potential, surface morphology, dispersion stability, aggregation, and sterility were determined and compared with pristine nGO nanoparticles (NPs). Our results show that PEGylation increased the particle sizes from 256.7 nm (pristine nGO) to 324.6 nm (nGO-PEG), the zeta potential from −32.9 to −21.6 mV, and wrinkled the surface of the nanosheets. Furthermore, nGO-PEG exhibited higher absorbance in the NIR region, as compared to unmodified nGO. PEGylated nGO demonstrated enhanced stability in aqueous solution, improved dispensability in the culture medium, containing 10% fetal bovine serum (FBS) and amended biocompatibility. A strong synergic effect of nGO-PEG activated with NIR irradiation for 5 min (1.5 W/cm−2 laser) was observed on cell growth inhibition of low invasive colon cancer cells (HT29) and their wound closure ability while the effect of NIR on cellular morphology was relatively weak. Our results show that PEGylation of nGO combined with NIR irradiation holds the potential for a biocompatible smart nanocarrier in colon cancer cells with enhanced physicochemical properties and higher biological compatibility. For that reason, further optimization of the irradiation process and detailed screening of nGO-PEG in combination with NIR and chemotherapeutics on the fate of the colon cancer cells is a prerequisite for highly efficient combined nanothermal and photothermal therapy for colon cancer.

Download Full-text

Effects of fatty acids on liver metastasis of ACL‐15 rat colon cancer cells

Nutrition and Cancer ◽

10.1080/01635589809514694 ◽

1998 ◽

Vol 31 (2) ◽

pp. 143-150 ◽

Cited By ~ 40

Author(s):

Shigeyoshi Iwamoto ◽

Hideto Senzaki ◽

Yasuhiko Kiyozuka ◽

Eliko Ogura ◽

Hideho Takada ◽

...

Keyword(s):

Fatty Acids ◽

Colon Cancer ◽

Liver Metastasis ◽

Cancer Cells ◽

Rat Colon ◽

Colon Cancer Cells

Download Full-text

Histological reactivity of a monoclonal antibody against rat colon cancer cells on human and rat normal gut and colonic tumours

Virchows Archiv A Pathological Anatomy and Histopathology ◽

10.1007/bf01600276 ◽

1992 ◽

Vol 420 (3) ◽

pp. 233-242 ◽

Cited By ~ 2

Author(s):

P. Genne ◽

N. -O. Olsson ◽

A. Caignard ◽

R. Oriol ◽

J. Bara ◽

...

Keyword(s):

Monoclonal Antibody ◽

Colon Cancer ◽

Cancer Cells ◽

Rat Colon ◽

Colon Cancer Cells ◽

Colonic Tumours

Download Full-text

Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors

International Journal of Cancer ◽

10.1002/ijc.2910320517 ◽

1983 ◽

Vol 32 (5) ◽

pp. 623-627 ◽

Cited By ~ 129

Author(s):

François Martin ◽

Anne Caignard ◽

Jean-François Jeannin ◽

Annick Leclerc ◽

Monique Martin

Keyword(s):

Colon Cancer ◽

Cancer Cells ◽

Rat Colon ◽

Colon Cancer Cells

Download Full-text

Lack of correlation between mdr-1 expression and volume-activation of cloride-currents in rat colon cancer cells

Pflügers Archiv - European Journal of Physiology ◽

10.1007/bf00374662 ◽

1995 ◽

Vol 430 (2) ◽

pp. 296-298 ◽

Cited By ~ 21

Author(s):

C. De Greef ◽

S. van der Heyden ◽

F. Viana ◽

J. Eggermont ◽

E. A. De Bruijn ◽

...

Keyword(s):

Colon Cancer ◽

Cancer Cells ◽

Rat Colon ◽

Colon Cancer Cells ◽

Volume Activation ◽

Mdr 1

Download Full-text

Recognition of a High Molecular Weight Glycoprotein (HMW-GP) Associated with Rat Colon Cancer Cells by Rat Monoclonal Antibodies

Hybridoma ◽

10.1089/hyb.1989.8.493 ◽

1989 ◽

Vol 8 (5) ◽

pp. 493-505 ◽

Cited By ~ 3

Author(s):

B. JANSSON ◽

T. BRODIN ◽

HANS OLOV SJÖGREN

Keyword(s):

Molecular Weight ◽

Colon Cancer ◽

Monoclonal Antibodies ◽

Cancer Cells ◽

High Molecular Weight ◽

Rat Colon ◽

Colon Cancer Cells

Download Full-text

Cetuximab-modified doxorubicin bovine serum albumin nanoparticles for the treatment of epidermal growth factor receptor-overexpressing colon cancer cells

Materials Express ◽

10.1166/mex.2021.2005 ◽

2021 ◽

Vol 11 (10) ◽

pp. 1619-1627

Author(s):

Yue Zhang ◽

Yuanfen Liu ◽

Yumin Hu ◽

Lei Pan

Keyword(s):

Colon Cancer ◽

Epidermal Growth Factor Receptor ◽

Bovine Serum Albumin ◽

Serum Albumin ◽

Cancer Cells ◽

Bovine Serum ◽

Growth Factor Receptor ◽

Colon Cancer Cells ◽

Albumin Nanoparticles ◽

Epidermal Growth

In this study, we developed an active targeting nano-immunoplatform of doxorubicin (DOX)-loaded bovine serum albumin (BSA) modified with the humanized antibody cetuximab, which can target the epidermal growth factor receptor (EGFR) of EGFR-overexpressing colon cancer, and subjected it to a series of in vitro evaluation. The obtained cetuximab-modified nanoparticles (cetuximab-DOX-immuno-NPs) had an average particle size of 218.2±2.2 nm, a polydispersity index of 0.162±0.023, a zeta potential of −23.28±0.75 mV, and a cetuximabloading efficiency of 33.6%±3.5%. The results of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity experiments showed that the cytotoxic of cetuximab-DOX-immuno-NPs in EGFR-overexpressing RKO colon cancer cells was significantly higher than it was in EGFR-under-expressing LS174 T cells. The results of flow cytometry showed that when DOX-immuno-NPs were used, DOX was eliminated soon after entering the cells, whereas when cetuximab-DOX-immuno-NPs were used, DOX efflux was reduced. Confocal laser-scanning microscopy was used to visualize the endocytosis of nanoparticles, and revealed that the fluorescence intensity of cetuximab-DOX-immuno-NPs was significantly higher than that of non-specific IgG-DOX-immuno-NPs in RKO cells. Moreover, in EGFR-under-expressing LS174 T cells, both cetuximab-DOXimmuno-NPs and Immunoglobulin G-DOX-immuno-NPs showed weak DOX fluorescence intensity, reflecting the specificity and selectivity of cetuximab-modified nanoparticles toward EGFR-overexpressing cancer cells. This study demonstrated that cetuximab modification of DOX-loaded BSA nanoparticles can increase their selectivity and reduce their toxicity. As this would decrease the side effects of these treatments in patients, this study shows that cetuximab-modified doxorubicin-loaded bovine serum albumin nanoparticles are promising candidates for targeted colon cancer therapy.

Download Full-text